Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The approval of the first type I recombinant collagen for medical aesthetics opens new growth opportunities for the company, with expectations for performance recovery in 2026 [1] - The company reported a total revenue of 55.19 billion yuan in 2025, a slight decrease of 0.37% year-on-year, and a net profit attributable to shareholders of 19.15 billion yuan, down 7.15% year-on-year [8] - The company has adjusted its profit forecasts for 2026 and 2027 downwards due to increased industry competition and short-term impacts on sales, with new profit estimates of 19.8 billion yuan and 22.7 billion yuan respectively [1] Financial Performance Summary - Revenue projections for the company are as follows: 2024A: 55.39 billion yuan, 2025A: 55.19 billion yuan, 2026E: 60.34 billion yuan, 2027E: 69.17 billion yuan, 2028E: 82.92 billion yuan [1] - Net profit projections are: 2024A: 20.62 billion yuan, 2025A: 19.15 billion yuan, 2026E: 19.78 billion yuan, 2027E: 22.70 billion yuan, 2028E: 26.58 billion yuan [1] - The company's earnings per share (EPS) are projected to be: 2024A: 1.93 yuan, 2025A: 1.79 yuan, 2026E: 1.85 yuan, 2027E: 2.12 yuan, 2028E: 2.48 yuan [1] - The price-to-earnings (P/E) ratios for the current price and latest diluted EPS are: 2024A: 14.10, 2025A: 15.19, 2026E: 14.70, 2027E: 12.81, 2028E: 10.94 [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is expected to experience a slight decline in performance in 2025, with revenue projected at 5.518 billion yuan (down 0.4% year-on-year) and net profit at 1.915 billion yuan (down 7.1% year-on-year) [3] - Despite the competitive industry landscape, the company is anticipated to maintain strong product capabilities and continue new iterations, leading to a reasonable valuation [3] - The forecast for net profit from 2026 to 2028 is set at 1.956 billion yuan, 2.184 billion yuan, and 2.445 billion yuan respectively, with corresponding EPS of 1.83 yuan, 2.04 yuan, and 2.28 yuan [3] Financial Summary - Revenue for 2025 is reported at 55.18 billion yuan, with a slight decline of 0.4% year-on-year, while net profit is 19.15 billion yuan, reflecting a decrease of 7.1% [3][4] - The gross margin for 2025 is 80.3%, down 1.8 percentage points, influenced by product category structure [4] - The company’s operating income is projected to grow to 6.120 billion yuan in 2026, with a year-on-year increase of 10.9% [6] - The P/E ratio is expected to be 14.8 in 2026, decreasing to 11.8 by 2028, indicating a favorable valuation trend [6] Product and Market Development - The company has received regulatory approval for two types of recombinant collagen medical devices, marking its entry into the skin rejuvenation market and demonstrating its R&D capabilities [5] - The product line includes the upgraded Collagen Stick 2.0 and the newly launched Collagen Big Mask King 3.0, which have received positive market feedback [5] - The company is expanding its market presence internationally, with products now available in Singapore, Malaysia, South Korea, and North America [5]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [4]. Core Insights - The company, 巨子生物 (2367.HK), reported a slight decline in revenue and profit for the year ending December 31, 2025, with total revenue of 55.19 billion yuan, down 0.37% year-on-year, and a net profit of 19.15 billion yuan, down 7.15% year-on-year [1]. - The company's gross margin was 80.34%, a decrease of 1.76 percentage points compared to the previous year, while the net profit margin fell to 34.70%, down 2.54 percentage points year-on-year [1]. - The second half of 2025 saw a significant impact from public sentiment issues, leading to a revenue drop of 19.76% and a net profit decline of 32.10% [1]. - The company is recognized as a leading player in the global recombinant collagen market, focusing on research and development to expand its eight consumer brands [4]. Financial Performance Summary - For 2025, the company achieved a revenue of 55.19 billion yuan, with a year-on-year decrease of 0.37%, and a net profit of 19.15 billion yuan, reflecting a 7.15% decline [1][6]. - The company forecasts net profits for 2026, 2027, and 2028 to be 19.49 billion yuan, 21.34 billion yuan, and 23.45 billion yuan, respectively, with corresponding price-to-earnings ratios of 15, 14, and 12 times [4][6]. - The revenue is expected to grow to 61.17 billion yuan in 2026, representing a year-on-year increase of 10.85% [6].

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [4]. Core Insights - The company, 巨子生物 (2367.HK), reported a slight decline in revenue and profit for the year ending December 31, 2025, with total revenue of 55.19 billion yuan, down 0.37% year-on-year, and a net profit of 19.15 billion yuan, down 7.15% year-on-year [1]. - The company's gross margin was 80.34%, a decrease of 1.76 percentage points compared to the previous year, while the net profit margin fell to 34.70%, down 2.54 percentage points year-on-year [1]. - In the second half of 2025, the company faced significant challenges due to public sentiment issues, leading to a 19.76% decline in revenue to 24.05 billion yuan and a 32.10% drop in net profit to 7.32 billion yuan [1]. - The company is recognized as a leading player in the global recombinant collagen market and is expanding its product portfolio across eight consumer brands [4]. Financial Performance Summary - For 2025, the company achieved a revenue of 55.19 billion yuan, with a year-on-year decline of 0.37%, and a net profit of 19.15 billion yuan, down 7.15% [1][6]. - The company forecasts net profits for 2026, 2027, and 2028 to be 19.49 billion yuan, 21.34 billion yuan, and 23.45 billion yuan respectively, with corresponding price-to-earnings ratios of 15, 14, and 12 [4][6]. - The revenue for 2026 is projected to increase to 61.17 billion yuan, reflecting a growth rate of 10.85% [6]. Brand Performance - The 可复美 brand generated revenue of 44.70 billion yuan in 2025, a slight decline of 1.58%, while the 可丽金 brand saw a revenue increase of 9.21% to 9.18 billion yuan [2]. - The company plans to launch significant new products in 2026, including an upgraded collagen stick and a new collagen repair series [2][3]. - Direct-to-consumer (DTC) sales through online channels accounted for 34.02 billion yuan, down 5.16%, while online sales through e-commerce platforms increased by 34.84% to 5.09 billion yuan [2].

Investment Rating - The report indicates a positive investment outlook for the beauty industry, with a projected retail sales growth of 5.1% in 2025, outperforming the overall retail market by 1.4 percentage points [7]. Core Insights - The beauty market is experiencing a recovery, with significant growth expected in the second half of 2025, particularly in online sales channels like Tmall and Douyin, despite a slowdown in Douyin's growth rate [6][7]. - The report highlights a shift in consumer preferences towards premium and specialized products, with categories like color cosmetics and personal care showing stronger growth compared to skincare [12]. - The competitive landscape is evolving, with domestic brands accelerating their multi-brand strategies, leading to an anticipated increase in industry concentration [19]. Summary by Sections Beauty Market Overview - The beauty market is projected to achieve a retail sales figure of 465.3 billion yuan in 2025, with a year-on-year growth of 5.1% [7]. - Online platforms such as Tmall and Douyin are expected to see varying growth rates, with Tmall recovering due to instant retail dynamics, while Douyin's growth is stabilizing [6]. Category Trends - Color cosmetics and personal care categories are expected to grow faster than skincare, with online sales across multiple platforms reaching 487.1 billion yuan, a year-on-year increase of 8.7% [12]. - New brands in personal care are emerging successfully, with notable growth rates for brands like Canban and OFF&RELAX [12]. Promotional Events - The Double Eleven shopping festival in 2025 is projected to generate a gross merchandise volume (GMV) of 1.695 trillion yuan, reflecting a 14% increase from 2024 [15]. - E-commerce platforms are focusing on instant retail to drive growth, with stable performance across various beauty categories during promotional periods [15]. Company Trends - Leading companies are rapidly developing multi-brand matrices, enhancing their operational capabilities and market presence [19]. - Companies like Shiseido and L'Oréal are showing signs of recovery in the high-end segment, while domestic brands are experiencing varied growth rates [31]. Medical Aesthetics - The medical aesthetics sector is seeing increased penetration, but competitive pressures are leading to price reductions [22]. - The report notes a shift from single-product offerings to more comprehensive product combinations in response to market demands [27]. Competitive Landscape - The beauty market is experiencing a K-shaped recovery, with high-end brands rebounding while mid-range brands face challenges [34]. - The report emphasizes the importance of brand strength and cost-effectiveness as key competitive factors in the current market environment [38].

Investment Rating - The investment rating for the company is "Outperform the Market" [6][4]. Core Insights - The company's short-term performance is impacted by public sentiment events and intensified industry competition, with projected revenue for 2025 at 55.19 billion, a year-on-year decrease of 0.4%, and adjusted net profit at 19.60 billion, down 8.9% year-on-year [2][4]. - The company anticipates a revenue growth rate of approximately 10% for 2026, with a slight decline in gross margin due to changes in product mix and rising raw material costs [2][4]. - The brand "可复美" generated revenue of 44.70 billion, a decrease of 1.6% year-on-year, while "可丽金" achieved revenue of 9.18 billion, an increase of 9.2% year-on-year, benefiting from online channel expansion and successful product upgrades [2][4]. Financial Performance Summary - Revenue from direct sales channels was 41.35 billion, remaining stable year-on-year, accounting for 74.9% of total revenue, while distribution channel revenue was 13.83 billion, down 1.5% year-on-year [3]. - The gross margin for 2025 is projected at 80.3%, down 1.8 percentage points year-on-year, with a net profit margin of 34.7%, down 2.5 percentage points year-on-year [3]. - The company plans to launch multiple skincare products in 2026, aiming to revitalize the performance of its functional skincare segment [4]. Earnings Forecast and Financial Metrics - The earnings forecast for 2025 includes revenue of 55.19 billion and net profit of 19.60 billion, with projections for 2026 and 2027 showing revenue growth of 9.6% and 7.3%, respectively [5][18]. - The projected PE ratios for 2026, 2027, and 2028 are 16, 15, and 14 times, respectively, reflecting adjustments due to public sentiment impacts and increased brand investment [4][5].

Investment Rating - The report maintains a "Buy" rating for the company, with a current price of HKD 30.70 and a fair value estimate of HKD 33.66 [4][9]. Core Insights - The company's performance is under short-term pressure, but there is optimism regarding the long-term value of its collagen products due to ongoing restructuring efforts [1][9]. - In 2025, the company reported revenue of RMB 55.2 billion, a slight decline of 0.4% year-on-year, and a net profit of RMB 19.1 billion, down 7.2% year-on-year [9][10]. - The report highlights a competitive industry landscape and changes in product structure that have led to a decrease in gross margin by 1.8 percentage points to 80.3% [9][10]. Financial Projections - Revenue is projected to grow from RMB 6.07 billion in 2026 to RMB 7.89 billion in 2028, with growth rates of 10.0%, 13.1%, and 14.9% respectively [2][10]. - The net profit is expected to increase from RMB 19.8 billion in 2026 to RMB 23.9 billion in 2028, with growth rates of 4%, 9%, and 11% respectively [10][11]. - The report anticipates a decline in overall gross margin to around 78%-79% during 2026-2028 due to a shift in product mix [10][11]. Business Segment Analysis - The efficacy skincare segment generated revenue of RMB 43.4 billion in 2025, showing a slight increase of 0.8% year-on-year, driven by enhanced marketing efforts [9][10]. - The medical beauty dressing segment saw revenue of RMB 11.6 billion, down 4.8% year-on-year, primarily due to price maintenance and channel sales control [9][10]. - Brand performance varied, with "可复美" (Kefumei) revenue declining by 1.6% to RMB 44.7 billion, while "可丽金" (Kelin) revenue increased by 9.2% to RMB 9.2 billion, benefiting from online channel expansion [9][10]. Channel Performance - Online direct-to-consumer (DTC) sales reached RMB 34.0 billion, down 5%, while e-commerce platform direct sales increased by 35% to RMB 5.1 billion [9][10]. - Offline direct sales grew by 32% to RMB 2.2 billion, supported by an increase in the number of cosmetic chain stores [9][10]. - Revenue from distributors decreased by 2% to RMB 13.8 billion due to pricing and channel management pressures [9][10]. Investment Recommendations - The company is in a critical phase of product matrix upgrade and channel structure optimization, with short-term performance adjustments expected to be absorbed [10][11]. - The report suggests that with the launch of new medical beauty products and improved online channel efficiency, the company is likely to return to a growth trajectory by 2026 [10][11].

Investment Rating - The investment rating for the company is "Buy" [1] Core Views - The company has reported its 2025 annual performance, achieving revenue of 5.519 billion yuan, a year-on-year decrease of 0.4%, and a net profit attributable to shareholders of 1.915 billion yuan, down 7.2% year-on-year [2] - The company plans to distribute a total dividend of 1.2104 yuan per share, amounting to approximately 1.29 billion yuan [2] - The company is expected to return to a growth trend in 2026, driven by new product launches and improved channel structures [8] Revenue Summary - In 2025, the company's revenue was 5.519 billion yuan, with a breakdown by product category showing functional skincare products at 4.337 billion yuan (+0.8% YoY), medical dressings at 1.16 billion yuan (-4.8% YoY), and health food and others at 0.22 billion yuan (+17.9% YoY) [3] - By brand, revenue from Kefu Mei was 4.47 billion yuan (-1.6% YoY), Keli Jin at 0.918 billion yuan (+9.2% YoY), and others at 0.22 billion yuan (+17.9% YoY) [3] - Revenue by channel showed DTC online sales at 3.402 billion yuan (-5.2% YoY), e-commerce platform sales at 0.509 billion yuan (+34.8% YoY), offline sales at 0.225 billion yuan (+32.3% YoY), and distribution at 1.383 billion yuan (-1.5% YoY) [3] Profitability Summary - The company's gross margin for 2025 was 80.34%, a decrease of 1.76 percentage points year-on-year, with a net profit margin of 34.70%, down 2.52 percentage points year-on-year [4] - The company’s operating expenses ratio for 2025 was 41.92%, an increase of 1.02 percentage points year-on-year, with significant increases in sales expenses [5] Product and Channel Development - The company is focusing on product development and channel construction to drive high-quality brand growth, with plans to launch new products and expand into new markets [6][7] - The company is enhancing its online operations and expanding its offline store presence, including entry into overseas markets such as Singapore and Malaysia [7] Financial Forecast - The company forecasts revenues of 6.113 billion yuan, 6.932 billion yuan, and 7.821 billion yuan for 2026, 2027, and 2028 respectively, with net profits of 1.950 billion yuan, 2.139 billion yuan, and 2.334 billion yuan for the same years [8][10] - The expected earnings per share (EPS) for 2026, 2027, and 2028 are 1.82 yuan, 2.00 yuan, and 2.18 yuan respectively, with corresponding price-to-earnings (PE) ratios of 16, 14, and 13 [8][10]

Core Viewpoint - The core strategic challenge for Giant Biological Management in 2026 is to balance brand strength and profit margin protection [5] Financial Performance - In 2025, Giant Biological reported revenue of 5.519 billion yuan, a year-on-year decrease of 0.4%, and a net profit attributable to shareholders of 1.915 billion yuan, down 7.2% [2] - Adjusted net profit for 2025 was 1.96 billion yuan, reflecting an 8.9% decline, with a gross margin of approximately 80.3%, down 1.8 percentage points [2] - This marks the first instance of revenue and net profit decline since the company's listing in 2022, contrasting with double-digit growth from 2022 to 2024 [2] Brand and Market Dynamics - The core brand, Cofu Mei, generated revenue of 4.47 billion yuan in 2025, accounting for over 80% of total revenue, but experienced a 1.6% decline, significantly impacting overall performance [4] - The decline in Cofu Mei's revenue is attributed to external shocks and intensified price competition within the industry [4] - The brand's online GMV during the 2025 Double Eleven shopping festival fell by approximately 30%, with a 20% decline on Tmall and a 50% drop on Douyin, primarily due to a strategic decision to avoid price wars [4] Cost Structure - In 2025, sales expenses increased by 2.4% due to ongoing investments in brand building, while management expenses rose by 11.9% due to personnel expansion and digital upgrades [3] - Research and development expenses decreased by 16.6%, reflecting a shift as some projects moved into the results conversion phase [3] Competitive Landscape - The market for collagen products is becoming increasingly competitive, with new entrants from traditional medical and pharmaceutical companies [6] - The brand's credibility was challenged when a beauty influencer questioned the collagen content in Cofu Mei's products, leading to a significant impact on brand reputation and sales [6] Future Strategies - Giant Biological plans to enhance innovation in raw material development and accelerate the approval of Class III medical devices [7] - The company aims to create replicable blockbuster products and launch new brands in emerging business sectors to drive revenue growth [7]

Investment Rating - The investment rating for the company is "Buy" [7] Core Insights - The company's revenue and profit margins are under pressure for 2025, primarily due to public sentiment and broadcasting impacts. The company has multiple new cosmetic products in the pipeline and has received approval for two medical beauty injectables, which are key areas to monitor for future performance [2][11]. Financial Summary - Total revenue for 2025 is projected at 5,519 million RMB, a slight decrease of 0.4% year-on-year. Net profit is expected to be 1,915 million RMB, down 7% year-on-year. The gross profit margin for 2025 is estimated at 80.34%, a decrease of 1.76 percentage points compared to the previous year [4][11]. - The company anticipates a revenue increase to 6,064 million RMB in 2026, with a projected net profit of 1,914 million RMB, remaining stable year-on-year [4][11]. - The company's PE ratio is expected to decrease from 22.89 in 2024 to 17.12 in 2025, indicating a more attractive valuation over time [4][11]. Brand and Product Development - The main brand, Kefu Mei, is experiencing a slight decline due to public sentiment and broadcasting efficiency issues. In 2025, Kefu Mei's revenue is expected to be 4,470 million RMB, a decrease of 2% year-on-year, while the Keli Jin brand is projected to grow by 9% to 917 million RMB [11]. - The company is focusing on enhancing its medical beauty business, with new products expected to launch in 2026, including collagen repair series and other functional skincare products [11].